Daily3h
Gilead Sciences sets aside USD 200 million to resolve HIV drug investigation
Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into ...
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
A Lethal Mystery Illness Spread in Congo. USAID Cuts Have Slowed the Response
Gutting USAID is already having a devastating impact around the world. In the Democratic Republic of Congo, teams that would ...
bhekisisa.org6h
The Global Fund will roll out the twice-yearly anti-HIV jab — with or without Pepfar
The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...
Lawyer Monthly5h
Gilead Sciences Sets Aside $200M for HIV Drug Settlement
Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.
Pepfar funding to fight HIV/AIDS has saved 26 million lives since 2003: how cutting it will hurt Africa
The US President's Emergency Plan for AIDS Relief has been a cornerstone of global HIV/AIDS prevention, care and treatment ...
Gilead price target raised to $132 from $115 at Oppenheimer
Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...